The European Medicines Agency gives a positive signal to UCB, the action takes a breath of fresh air

The doors of the European market are about to open for bimekizumab, a treatment developed by the Belgian pharmaceutical group UCB. Indeed, the European Medicines Agency has just accepted the regulatory review of two marketing authorization applications for bimekizumab for the treatment of adult patients with active psoriatic arthritis, and adult patients with axial spondyloarthritis active.

Good news – although it is not yet a formal authorization – for the company, whose title has been under pressure in recent months. The action took 1.85% on Tuesday morning shortly after the opening. What remains a timid increase.

“A decisive step”

Citi Research had also raised its price target to 75 euros on Monday, moving from the “sell” advice to “neutral” pending good news for the American market for Bimzelx (bimekizumab). This news in Europe will comfort the analyst.

These two applications for psoriatic arthritis and axial spondyloarthritis represent an important milestone for bimekizumab, as well as a decisive step towards expanding treatment options in the EU for these debilitating diseases.“, for his part declared Emmanuel Caeymaex, executive vice-president of UCB.

Leave a Comment

Your email address will not be published.